Adjuvant Statin Therapy for Esophageal Adenocarcinoma: a cost-effectiveness analysis

Rebekah Fong Soe Khioe (Lead Author), Chris Skedgel, Andrew Hart, Mike Lewis, Leo Alexandre

Research output: Contribution to journalArticle

3 Citations (Scopus)
16 Downloads (Pure)

Abstract

Background: Emerging preclinical evidence indicates statins, medications commonly used in the prevention of cardiovascular disease, inhibit proliferation, promote apoptosis and limit invasiveness of esophageal adenocarcinoma (EAC). Population-based observational data demonstrates statin treatment after diagnosis of EAC is associated with significant reductions in all-cause and cancer-specific mortality. A feasibility study of adjuvant statin therapy following potentially curative resection for EAC has completed, with planned progression to a full phase III randomised controlled trial

Aim: To estimate the cost-utility of statin therapy following surgical resection for EAC from an NHS perspective.

Methods: A Markov model was developed to estimate the costs and outcomes (quality adjusted life years, QALYs) for hypothetical cohorts of patients with EAC exposed or not exposed to statins following potentially curative surgical resection. Model parameters were based on estimates from published observational and trial data. Costs, utilities and transition probabilities were modelled to reflect clinical practice from a payer’s perspective. Probabilistic and one-way sensitivity analyses were performed to account for uncertainty in key parameters.

Results: Overall, a cost-saving of £6,781 per patient was realised with statin treatment compared to no statins. In probabilistic sensitivity analysis, 99% of all iterations were cost-saving and 99% of all iterations were less than £20,000 per QALY gained. These results were robust to changes in the price and effectiveness of statins.

Conclusions: The cohort exposed to statins had lower costs and better QALY outcomes than the no statin cohort. Assuming a causal relationship between statin exposure and outcomes suggests that statins following resection of EAC is a cost-saving treatment.
Original languageEnglish
Pages (from-to)349–358
Number of pages10
JournalPharmacoEconomics
Volume36
Issue number3
Early online date5 Dec 2017
DOIs
Publication statusPublished - Mar 2018

Keywords

  • HMG-CoA
  • cost-effectiveness
  • esophageal cancer

Cite this